scholarly journals Mesenchymal Stromal Cell Therapy for Pancreatitis: A Systematic Review

2018 ◽  
Vol 2018 ◽  
pp. 1-14 ◽  
Author(s):  
Sara M. Ahmed ◽  
Mahmoud Morsi ◽  
Nehal I. Ghoneim ◽  
Mohamed M. Abdel-Daim ◽  
Nagwa El-Badri
Keyword(s):  
Clinical Trials ◽  
Acute Pancreatitis ◽  
Chronic Pancreatitis ◽  
Cell Therapy ◽  
Animal Studies ◽  
Meta Analysis ◽  
Cell Types ◽  
Inclusion Criteria ◽  
Acute And Chronic Pancreatitis ◽  
Substantial Heterogeneity

Background. Based on animal studies, adult mesenchymal stromal cells (MSCs) are promising for the treatment of pancreatitis. However, the best type of this form of cell therapy and its mechanism of action remain unclear. Methods. We searched the PubMed, Web of Science, Scopus, Google Scholar, and Clinical Trials.gov websites for studies using MSCs as a therapy for both acute and chronic pancreatitis published until September 2017. Results. We identified 276 publications; of these publications, 18 met our inclusion criteria. In animal studies, stem cell therapy was applied more frequently for acute pancreatitis than for chronic pancreatitis. No clinical trials were identified. MSC therapy ameliorated pancreatic inflammation in acute pancreatitis and pancreatic fibrosis in chronic pancreatitis. Bone marrow and umbilical cord MSCs were the most frequently administered cell types. Due to the substantial heterogeneity among the studies regarding the type, source, and dose of MSCs used, conducting a meta-analysis was not feasible to determine the best type of MSCs. Conclusion. The available data were insufficient for determining the best type of MSCs for the treatment of acute or chronic pancreatitis; therefore, clinical trials investigating the use of MSCs as therapy for pancreatitis are not warranted.

scholarly journals Association between Oral Hygiene and Metabolic Syndrome: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 (13) ◽  
pp. 2873
Author(s):  
Cornelia Melinda Adi Santoso ◽  
Fera Ketti ◽  
Taufan Bramantoro ◽  
Judit Zsuga ◽  
Attila Nagy
Keyword(s):  
Systematic Review ◽  
Metabolic Syndrome ◽  
Oral Hygiene ◽  
Reference Lists ◽  
Meta Analysis ◽  
Tooth Brushing ◽  
Inclusion Criteria ◽  
Poor Oral Hygiene ◽  
Dental Visits ◽  
Substantial Heterogeneity

Emerging evidence has linked poor oral hygiene to metabolic syndrome (MetS), but previously, no summary of evidence has been conducted on the topic. This systematic review and meta-analysis aims to evaluate the associations of oral hygiene status and care with MetS. A systematic search of the PubMed and Web of Science databases from inception to March 17, 2021, and examination of reference lists was conducted to identify eligible observational studies. A random-effects model was applied to pool the effects of oral hygiene status and care on MetS. Thirteen studies met the inclusion criteria and had sufficient methodological quality. Good oral hygiene status (OR = 0.30 (0.13–0.66); I2 = 91%), frequent tooth brushing (OR = 0.68 (0.58–0.80); I2 = 89%), and frequent interdental cleaning (OR = 0.89 (0.81–0.99); I2 = 27%) were associated with a lower risk of MetS. Only one study examined the association between dental visits and MetS (OR = 1.10 (0.77–1.55)). Our findings suggested that there might be inverse associations of oral hygiene status, tooth-brushing frequency, and interdental cleaning with MetS. However, substantial heterogeneity for tooth-brushing frequency and inconsistent results for oral hygiene status in subgroup analyses were observed. There was insufficient evidence for the association between dental visits and MetS. Further longitudinal studies are needed to investigate these associations.

Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: results from a meta-analysis of large animal studies

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P1462-P1462
Author(s):  
S. J. Jansen Of Lorkeers ◽  
J. E. C. Eding ◽  
T. I. G. Van Der Spoel ◽  
H. M. Vesterinen ◽  
S. Koudstaal ◽  
...  
Keyword(s):  
Heart Disease ◽  
Cell Therapy ◽  
Ischemic Heart Disease ◽  
Animal Studies ◽  
Meta Analysis ◽  
Ischemic Heart ◽  
Large Animal ◽  
Allogeneic Cell ◽  
Allogeneic Cell Therapy

scholarly journals Positive predictive value of acute and chronic pancreatitis diagnoses in the Danish National Patient Registry: A validation study

2018 ◽  
Vol 48 (1) ◽  
pp. 14-19 ◽  
Author(s):  
Jakob Kirkegård ◽  
Marie R. Mortensen ◽  
Ida R. Johannsen ◽  
Frank V. Mortensen ◽  
Deirdre Cronin-Fenton
Keyword(s):  
Acute Pancreatitis ◽  
Chronic Pancreatitis ◽  
Positive Predictive Value ◽  
Predictive Value ◽  
Medical Records ◽  
Patient Registry ◽  
National Patient Registry ◽  
Danish National Patient Registry ◽  
National Patient ◽  
Acute And Chronic Pancreatitis

Aims: To examine the validity of the diagnoses of acute and chronic pancreatitis registered in the Danish National Patient Registry. Methods: We identified all patients in the Danish National Patient Registry admitted to two Danish hospitals with acute or chronic pancreatitis from 1996 to 2013. From this population, we randomly sampled 100 patients with acute pancreatitis and 100 patients with chronic pancreatitis. For each cohort, we computed the positive predictive values and associated 95% confidence intervals (CIs) for the discharge diagnosis of acute or chronic pancreatitis using medical records as the gold standard. Results: We identified 2617 patients with acute pancreatitis and 1284 patients with chronic pancreatitis discharged from either of the two hospitals during the study period. Of these, 776 (19.9%) had a diagnosis of both acute and chronic pancreatitis and are thus present in both cohorts. From the 200 sampled patients, a total of 138 (69.0%) medical records were available for review. The positive predictive value for a diagnosis of acute pancreatitis in the Danish National Patient Registry was 97.3% (95% CI 90.5–99.2%) and for chronic pancreatitis 83.1% (95% CI 72.2–90.3%). Conclusions: The validity of diagnoses of acute and chronic pancreatitis registered in the Danish National Patient Registry since 1996 is generally high.

Determination of Plasma Glycoprotein 2 Levels in Patients With Pancreatic Disease

2004 ◽  
Vol 128 (6) ◽  
pp. 668-674 ◽  
Author(s):  
Ying Hao ◽  
Jing Wang ◽  
Ningguo Feng ◽  
Anson W. Lowe
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Chronic Pancreatitis ◽  
Tertiary Care ◽  
Pancreatic Disease ◽  
Pancreatic Acinar Cell ◽  
Enzyme Linked Immunosorbent Assay ◽  
Assay Sensitivity ◽  
Acute And Chronic Pancreatitis

Abstract Context.—Blood tests possessing higher diagnostic accuracy are needed for all the major pancreatic diseases. Glycoprotein 2 (GP2) is a protein that is specifically expressed by the pancreatic acinar cell and that has previously shown promise as a diagnostic marker in animal models of acute pancreatitis. Objective.—This study describes the development of an assay for GP2, followed by the determination of plasma GP2 levels in patients with acute pancreatitis, chronic pancreatitis, and pancreatic cancer. Design.—Rabbit polyclonal antisera and mouse monoclonal antibodies were generated against human GP2 and used to develop an enzyme-linked immunosorbent assay. The assay was tested in patients with an admitting diagnosis of pancreatic disease at 2 tertiary care facilities. The diagnosis of acute or chronic pancreatitis and pancreatic cancer was determined using previously established criteria that incorporated symptoms, radiology, pathology, and serology. Plasma GP2 levels were determined in 31 patients with acute pancreatitis, 16 patients with chronic pancreatitis, 36 patients with pancreatic cancer, and 143 control subjects without pancreatic disease. Amylase and lipase levels were also determined in patients with acute pancreatitis. Results.—The GP2 assay's sensitivity values were 0.94 for acute pancreatitis, 0.81 for chronic pancreatitis, and 0.58 for pancreatic cancer, which were greater than the 0.71 for acute pancreatitis and 0.43 for chronic pancreatitis (P = .02) observed for amylase. The lipase assay sensitivity for acute pancreatitis was 0.66. The accuracy of the GP2 assay was greater than that of the amylase or lipase assays for acute pancreatitis (GP2 vs lipase, P = .004; GP2 vs amylase, P = .003) when analyzed using receiver operator characteristic curves. When daily serial blood samples were obtained for 13 patients with acute pancreatitis, GP2 levels remained abnormally elevated for at least 1 day longer than the amylase or lipase levels. Conclusion.—The GP2 assay is a useful new marker for acute and chronic pancreatitis.

Intra-arterial chemotherapy for retinoblastoma: an updated systematic review and meta-analysis

2019 ◽  
Vol 11 (12) ◽  
pp. 1266-1272 ◽  
Author(s):  
Krishnan Ravindran ◽  
Lauren A Dalvin ◽  
Jose S Pulido ◽  
Waleed Brinjikji
Keyword(s):  
Metastatic Disease ◽  
Meta Analysis ◽  
Inclusion Criteria ◽  
First Line ◽  
Short Term ◽  
Systemic Complications ◽  
Substantial Heterogeneity ◽  
Insight Into

Background and purposeIntra-arterial chemotherapy for retinoblastoma has been adopted as a first-line treatment option by numerous tertiary centers. The effect of intra-arterial chemotherapy on future rates of metastatic disease as well as on globe salvage in advanced eyes remains relatively unknown.MethodsA search of PubMED, MEDLINE, EMBASE, and Web of Science electronic databases was conducted from inception until January 2019 for studies with a minimum of 10 patients reporting outcomes and complications following intra-arterial chemotherapy for retinoblastoma.ResultsA total of 20 studies met the inclusion criteria for analysis, comprising 873 patients and 1467 eyes. Only one study was comparative; there was substantial heterogeneity in reported outcomes and several overlapping patient cohorts that were published. Across all studies, 174 of 1467 eyes were enucleated (11.8%). Metastatic disease occurred in 8 of 513 patients (1.6%). Globe salvage was achieved in 318 of 906 (35.6%) cases of advanced retinoblastoma. The most common ocular complication was retinal detachment, occurring in 23% of eyes, and the most common systemic complications were transient fever and nausea/vomiting.ConclusionsThere is a paucity of higher-level evidence with adequate follow-up surrounding the long-term safety of intra-arterial chemotherapy and effect on metastasis in retinoblastoma. Studies to date have been limited by short-term follow-up. Longitudinal prospective studies could provide greater insight into the ability of intra-arterial chemotherapy to reduce the risk of retinoblastoma metastasis.

scholarly journals Opioid-induced constipation in palliative care: state of the art

2020 ◽  
pp. 1116-1124
Author(s):  
Erlania do Carmo Freitas ◽  
Geslaney Reis da Silva ◽  
Rudval Souza da Silva ◽  
Rita Narriman Silva de Oliveira Boery ◽  
Maria Patricia Milagres
Keyword(s):  
Palliative Care ◽  
Clinical Trials ◽  
Adverse Effects ◽  
Exploratory Study ◽  
Adverse Reactions ◽  
State Of The Art ◽  
Meta Analysis ◽  
Life Quality ◽  
Limited Data ◽  
Inclusion Criteria

OBJECTIVE: The study’s purpose has been to address the state of the art in investigations such as clinical trials, systematic reviews with meta-analysis and case studies, which report how to minimize opioid-induced constipation in patients undergoing palliative care. METHODS: This is an exploratory study through an integrative review of four databases addressing published articles from 2013 to 2017. RESULTS: A total of 117 publications were presented, which 17 presented the inclusion criteria. The studies describe the prevalence of constipation rates induced by the use of opioids. CONCLUSION: Although these drugs alleviate pain, the adverse reactions may generate discomfort and loss of the patient’s life quality. There are limited data on the treatment of constipation. It was observed that few authors mentioned diet as a helper on this situation, emphasizing the use of medications. Further studies should be encouraged aiming to find the balance between analgesia and reduction of adverse effects.

scholarly journals Effectiveness of Salvia Officinalis on Mediation of Serum Lipid in Clinical Trials: Systematic Review and Meta-analysis (P12-004-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Sepideh Alasvand ◽  
WIlliam Bridges ◽  
Vivian Haley-Zitlin
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Chronic Disease ◽  
Serum Lipid ◽  
Animal Studies ◽  
Serum Lipids ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Salvia Officinalis ◽  
Lipoprotein Cholesterol

Abstract Objectives The present systematic review and meta-analysis investigates the effectiveness of S. officinalis leaves in management of dyslipidemia of chronic disease. Dyslipidemia is one of the main indicators of cardiovascular disease (CVD). It is typically characterized by elevated levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL) and triglyceride (TG) along with reduction of high-density lipoprotein cholesterol (HDL) in blood. The handling of dyslipidemia is a crucial factor in the general control of the cardiovascular risk in individuals suffering from diseases such as diabetes, CVD or hypertension. Plant foods have played an important role in chronic disease management. S. officinalis leaves (sage) have been identified as improving glucose homeostasis and serum lipids in animal and human models. Methods PubMed, FSTA, Web of Science, CINAHEL and MEDLINE databases were searched using keywords (“Serum lipids” OR triglyceride* OR cholesterol* OR “LDL” OR “HDL” OR dyslipidemia) AND (sage or "Salvia officinalis") up to January 2019. Review articles, animal studies, non-trial, non-specific related plants, and articles which did not examine lipid profiles were included in the exclusion criteria. Articles that met the inclusion criteria included effects of administration of Salvia officinalis on serum lipid in clinical trials. All statistical calculations were performed using SAS software version 9.2 (SAS, Cary NC, USA). Results From 243 studies, four of the trials met the selection criteria of the meta-analysis. Salvia officinalis significantly improved serum lipids. The estimated value for TC was −52.64 mg/dl, 95% CI: −71.0505 to −34.23, P = 0.0001 and LDL −23.28 mg/dl, 95% CI: −40.07 to −6.48, P = 0.006. Moreover, TG was −74.98 mg/dl, 95% CI: −129.16 to −20.8190, P = 0.006 and HDL-C at 6.3424 mg/dl, 95% CI: 1.58 to 11.1033, P = 0.009) was significantly improved after Salvia officinalis administration Conclusions Although the systematic review and meta-analysis investigation involved few studies it revealed promising efficiency of Salvia officinalis on improving the serum lipids in clinical trials and suggested that Salvia officinalis can be an appropriate plant food to manage dyslipidemia of chronic diseases. Funding Sources N/A.

scholarly journals Comparative clinical trials in psychotherapy: Have large effects been replicated?

2020 ◽  
Vol 29 ◽  
Author(s):  
Nickolas D. Frost ◽  
Thomas W. Baskin ◽  
Bruce E. Wampold
Keyword(s):  
Clinical Trials ◽  
Treatment Efficacy ◽  
Literature Search ◽  
Meta Analysis ◽  
Effect Sizes ◽  
Depression And Anxiety ◽  
Inclusion Criteria ◽  
Average Quality ◽  
Meta Analyses

Abstract Aims The purpose of this review is to examine the replication attempts of psychotherapy clinical trials for depression and anxiety. We focus specifically on replications of trials that exhibit large differences between psychotherapies. The replicability of these trials is especially important for meta-analysis, where the inclusion of false-positive trials can lead to erroneous conclusions about treatment efficacy. Methods Standard replication criteria were developed to distinguish direct from conceptual replication methodologies. Next, an exhaustive literature search was conducted for published meta-analyses of psychotherapy comparisons. Trials that exhibited large effects (d > 0.8) were culled from these meta-analyses. For each trial, a cited replication was conducted to determine if the trial had been subsequently replicated by either ‘direct’ or ‘conceptual’ methods. Finally, a broader search was conducted to examine the extent of replication efforts in the psychotherapy literature overall. Results In the meta-analytic search, a total of N = 10 meta-analyses met the inclusion criteria. From these meta-analyses, N = 12 distinct trials exhibited large effect sizes. The meta-analyses containing more than two large effect trials reported evidence for treatment superiority. A cited replication search yielded no direct replication attempts (N = 0) for the trials with large effects, and N = 4 conceptual replication attempts of average or above average quality. However, of these four attempts, only two partially corroborated the results from their original trial. Conclusion Meta-analytic reviews are influenced by trials with large effects, and it is not uncommon for these reviews to contain several such trials. Since we find no evidence that trials with such large effects are directly replicable, treatment superiority conclusions from these reviews are highly questionable. To enhance the quality of clinical science, the development of authoritative replication criteria for clinical trials is needed. Moreover, quality benchmarks should be considered before trials are included in a meta-analysis, or replications are attempted.

scholarly journals Trends in clinical trials for stroke by cell therapy: data mining ClinicalTrials.gov and the ICTRP portal site

2019 ◽  
Vol 4 (1) ◽  
Author(s):  
Takaharu Negoro ◽  
Hanayuki Okura ◽  
Midori Maehata ◽  
Shigekazu Hayashi ◽  
Satoru Yoshida ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cell Therapy ◽  
Chronic Phase ◽  
Cell Types ◽  
Phase Iii ◽  
Definitive Treatment ◽  
Stroke Treatment ◽  
Portal Site ◽  
Therapy Studies ◽  
Phase Iii Studies

Abstract Definitive treatment of stroke constitutes an important thesis of regenerative medicine in the cerebrovascular field. However, to date, no cell therapy products for stroke are yet on the market. In this study, we examined the clinical research trends related to cell therapy products in the stroke field based on data obtained from the ClinicalTrials.gov website and International Clinical Trials Research Platform (ICTRP) portal site. These data do not offer results of clinical trials comprehensively but provide information regarding various attributes of planned clinical trials including work in progress. We selected 78 cell therapy studies related to the field of stroke treatment from ClinicalTrial.gov and ICTRP. These were analyzed according to, e.g., the reporting countries, origin (autologous or allogeneic), of cell used, cell types and source organs, the progress of translational phases, target phase of the disease (acute or chronic stroke), and route of administration. This analysis revealed a trend whereby in the acute phase, mesenchymal stem cells were administered intravenously at a relatively higher dose, whereas in the chronic phase a small number of cells were administered intracranially. Only two randomized controlled Phase III studies with over 100 patients are registered, but none of them has been completed. Thus, cell therapy against stroke appears to constitute a premature area compared with cartilage repair as assessed in our previous report. In addition, tracking by means of the ID number of each trial via PubMed revealed that 44% of clinical studies in this field have corresponding published results, which was also discussed.

Sign in / Sign up

Export Citation Format

Share Document